WHO-klassificeringen i 2008 af lymfoide neoplasmer og fortid: ideer under udvikling og fornuftige formål
Verdenssundhedsorganisationens klassificering af lymfoide neoplasmer opdateret i 2008 repræsenterer en verdensomspændende enighed om diagnosen af disse tumorer og er baseret på anerkendelsen af forskellige sygdomme ved hjælp af en tværfaglig tilgang. Den opdaterede klassificering forbedrede definitionerne af velkendte sygdomme, identificerede nye enheder og varianter og inkorporerede nye begreber i forståelsen af lymfoide neoplasmer.
- Nogle spørgsmål var imidlertid uafviklede, såsom i hvilket omfang specifikke genetiske eller molekylære ændringer definerer visse tumorer, og standing som foreløbige enheder, kategorier, som arbejdsgrupperne fra Verdenssundhedsorganisationen mente, at der ikke var tilstrækkelig bevis til at anerkende som forskellige sygdomme ved dette tid.
- Derudover er der siden offentliggørelsen blevet genereret nye fund og ideer. Denne gennemgang opsummerer den videnskabelige begrundelse for klassificeringen og understregede ændringer, der har haft effekt på praksisretningslinjerne.
- Forfatterne adresserer kriterierne og betydningen af tidlige eller forløberlæsioner og identificeringen af visse lymfoide neoplasmer, der stort set er forbundet med bestemte aldersgrupper, såsom børn og ældre.
- Spørgsmålet om grænsekategorier, der har overlappende funktioner med retailer B-celle lymfomer, samt flere midlertidige enheder, gennemgås. Disse nye observationer kortlægger et kursus for fremtidig forskning på området.

Recombinant T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) |
4-RPB709Ra01 |
Cloud-Clone |
-
EUR 623.20
-
EUR 290.40
-
EUR 2006.98
-
EUR 748.99
-
EUR 1377.98
-
EUR 492.00
-
EUR 4837.44
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat T-Cell Leukemia/Lymphoma Protein 1A expressed in: E.coli |
TCL1A T-cell Leukemia/Lymphoma 1A Human Recombinant Protein |
PROTP56279 |
BosterBio |
Regular: 50ug |
EUR 380.4 |
Description: TCL1A Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 114 amino acids (1-114 a.a.) and having a molecular mass of 13.4kDa.;The TCL1A is purified by proprietary chromatographic techniques. |
Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Protein |
20-abx069248 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Antibody |
20-abx103881 |
Abbexa |
-
EUR 493.20
-
EUR 159.60
-
EUR 1378.80
-
EUR 678.00
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
T-Cell Leukemia/lymphoma Protein 1A (TCL1A) Antibody |
20-abx103882 |
Abbexa |
-
EUR 526.80
-
EUR 159.60
-
EUR 1479.60
-
EUR 710.40
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
T-Cell Leukemia/lymphoma Protein 1A (TCL1A) Antibody |
20-abx000786 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
T-Cell Leukemia/lymphoma Protein 1A (TCL1A) Antibody |
abx433350-200ul |
Abbexa |
200 ul |
EUR 460.8 |
|
T-Cell Leukemia/lymphoma Protein 1A (TCL1A) Antibody |
20-abx313149 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
T-Cell Leukemia/lymphoma Protein 1A (TCL1A) Antibody |
abx218926-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
T-Cell Leukemia/lymphoma Protein 1A (TCL1A) Antibody |
abx224110-100ug |
Abbexa |
100 ug |
EUR 493.2 |
|
T-Cell Leukemia/lymphoma Protein 1A (TCL1A) Antibody |
abx238559-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
Human T-cell leukemia/lymphoma protein 1A (TCL1A) ELISA Kit |
abx518206-96tests |
Abbexa |
96 tests |
EUR 801.6 |
|
Human TCL1A/ T-cell leukemia/lymphoma protein 1A ELISA Kit |
E2460Hu |
Sunlong |
1 Kit |
EUR 685.2 |
Human T- cell leukemia/lymphoma protein 1A, TCL1A ELISA KIT |
ELI-05546h |
Lifescience Market |
96 Tests |
EUR 988.8 |
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Polyclonal Antibody (Human) |
4-PAB709Hu01 |
Cloud-Clone |
-
EUR 286.80
-
EUR 2869.20
-
EUR 717.60
-
EUR 358.80
-
EUR 253.20
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) |
Human T-Cell Leukemia/Lymphoma Protein 1A(TCL1A)ELISA Kit |
QY-E04512 |
Qayee Biotechnology |
96T |
EUR 433.2 |
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Polyclonal Antibody (Human), APC |
4-PAB709Hu01-APC |
Cloud-Clone |
-
EUR 399.60
-
EUR 3735.60
-
EUR 1046.40
-
EUR 507.60
-
EUR 258.00
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A). This antibody is labeled with APC. |
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Polyclonal Antibody (Human), Biotinylated |
4-PAB709Hu01-Biotin |
Cloud-Clone |
-
EUR 363.60
-
EUR 2809.20
-
EUR 836.40
-
EUR 442.80
-
EUR 259.20
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A). This antibody is labeled with Biotin. |
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Polyclonal Antibody (Human), Cy3 |
4-PAB709Hu01-Cy3 |
Cloud-Clone |
-
EUR 483.60
-
EUR 4930.80
-
EUR 1345.20
-
EUR 627.60
-
EUR 294.00
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A). This antibody is labeled with Cy3. |
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Polyclonal Antibody (Human), FITC |
4-PAB709Hu01-FITC |
Cloud-Clone |
-
EUR 344.40
-
EUR 3012.00
-
EUR 860.40
-
EUR 430.80
-
EUR 230.40
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A). This antibody is labeled with FITC. |
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Polyclonal Antibody (Human), HRP |
4-PAB709Hu01-HRP |
Cloud-Clone |
-
EUR 366.00
-
EUR 3256.80
-
EUR 926.40
-
EUR 459.60
-
EUR 243.60
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A). This antibody is labeled with HRP. |
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Polyclonal Antibody (Human), PE |
4-PAB709Hu01-PE |
Cloud-Clone |
-
EUR 344.40
-
EUR 3012.00
-
EUR 860.40
-
EUR 430.80
-
EUR 230.40
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A). This antibody is labeled with PE. |
Mouse T-cell leukemia/lymphoma protein 1A (TCL1A) ELISA Kit |
abx518207-96tests |
Abbexa |
96 tests |
EUR 801.6 |
|
Mouse T- cell leukemia/lymphoma protein 1A, Tcl1a ELISA KIT |
ELI-05545m |
Lifescience Market |
96 Tests |
EUR 1038 |
T-Cell Leukemia/Lymphoma Protein 1A (TCL1A) Polyclonal Antibody (Human), APC-Cy7 |
4-PAB709Hu01-APC-Cy7 |
Cloud-Clone |
-
EUR 656.40
-
EUR 7327.20
-
EUR 1948.80
-
EUR 872.40
-
EUR 372.00
|
- 100ul
- 10ml
- 1ml
- 200ul
- 20ul
|
|
Description: A Rabbit polyclonal antibody against Human T-Cell Leukemia/Lymphoma Protein 1A (TCL1A). This antibody is labeled with APC-Cy7. |
Recombinant human T-cell leukemia/lymphoma protein 1B |
P1275 |
FN Test |
100ug |
Ask for price |
|
Description: Recombinant protein for human T-cell leukemia/lymphoma protein 1B |
TCL1B T-cell Leukemia/Lymphoma 1B Human Recombinant Protein |
PROTO95988 |
BosterBio |
Regular: 20ug |
EUR 380.4 |
Description: TCL1B Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 151 amino acids (1-128a.a) and having a molecular mass of 17.2kDa. TCL1B is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. |
T-cell Leukemia / Lymphoma 1B Protein |
20-abx261196 |
Abbexa |
-
EUR 4101.60
-
EUR 393.60
-
EUR 276.00
|
|
|
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric, Trial Size |
CBA-135-T |
Cell Biolabs |
24 assays |
EUR 518.4 |
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
CytoSelect 96-Well Cell Transformation Assay (Cell Recovery Compatible, Fluorometric), Trial Size |
CBA-140-T |
Cell Biolabs |
24 assays |
EUR 547.2 |
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
CytoSelect 24-Well Cell Migration Assay (8 µm, Colorimetric Format), Trial Size |
CBA-100-T |
Cell Biolabs |
4 assays |
EUR 358.8 |
Description: Chemotaxis describes the movement of cells toward or away from a chemical stimulus in their environment. Cell chemotaxis plays a pivotal role in the progression of cancer and other diseases. CytoSelect Cell Migration Assays are ideal for determining the chemotactic properties of cells. The 8 µm pore size is suitable for most cell types including epithelial cells, fibroblasts, and cancer cell lines. |
CytoSelect 24-Well Cell Migration Assay (8 µm, Fluorometric Format), Trial Size |
CBA-101-T |
Cell Biolabs |
4 assays |
EUR 358.8 |
Description: Chemotaxis describes the movement of cells toward or away from a chemical stimulus in their environment. Cell chemotaxis plays a pivotal role in the progression of cancer and other diseases. CytoSelect Cell Migration Assays are ideal for determining the chemotactic properties of cells. The 8 µm pore size is suitable for most cell types including epithelial cells, fibroblasts, and cancer cell lines. |
CytoSelect 24-Well Cell Migration Assay (5 µm, Fluorometric Format), Trial Size |
CBA-102-T |
Cell Biolabs |
4 assays |
EUR 358.8 |
Description: Chemotaxis describes the movement of cells toward or away from a chemical stimulus in their environment. Cell chemotaxis plays a pivotal role in the progression of cancer and other diseases. CytoSelect Cell Migration Assays are ideal for determining the chemotactic properties of cells. The 5 µm pore size is ideal for monocytes / macrophages. |
CytoSelect 24-Well Cell Migration Assay (3 µm, Fluorometric Format), Trial Size |
CBA-103-T |
Cell Biolabs |
4 assays |
EUR 358.8 |
Description: Chemotaxis describes the movement of cells toward or away from a chemical stimulus in their environment. Cell chemotaxis plays a pivotal role in the progression of cancer and other diseases. CytoSelect Cell Migration Assays are ideal for determining the chemotactic properties of cells. The 3 µm pore size is best for the smallest cells including neutrophils and other leukocytes. |
CytoSelect 24-Well Cell Invasion Assay (Basement Membrane, Colorimetric Format), Trial Size |
CBA-110-T |
Cell Biolabs |
4 assays |
EUR 386.4 |
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 24-well plates on either a standard microplate reader or a fluorescence plate reader. Inserts are precoated on the top of the membrane with ECM matrix gel (basement membrane), a protein mix isolated from EHS tumor cells. |
CytoSelect 24-Well Cell Invasion Assay (Basement Membrane, Fluorometric Format), Trial Size |
CBA-111-T |
Cell Biolabs |
4 assays |
EUR 386.4 |
Description: The ability of malignant tumor cells to invade normal surrounding tissue contributes in large part to the morbidity and mortality of cancers. Cell invasion requires several distinct cellular functions including adhesion, motility, detachment, and extracellular matrix proteolysis. Our CytoSelect Cell Invasion Assays utilize precoated inserts to assay the invasive properties of tumor cells. Invasive cells can be quantified in 24-well plates on either a standard microplate reader or a fluorescence plate reader. Inserts are precoated on the top of the membrane with ECM matrix gel (basement membrane), a protein mix isolated from EHS tumor cells. |
CytoSelect 96-Well Cell Transformation Assay (Soft Agar Colony Formation), Trial Size |
CBA-130-T |
Cell Biolabs |
24 assays |
EUR 463.2 |
Description: Our CytoSelect 96-Well Cell Transformation Assay (Soft Agar Colony Formation) is suitable for measuring cell transformation where no downstream analysis is required. Cells are incubated in a semisolid agar medium for 7-8 days. The cells are then solubilized, lysed and detected using the included fluorescent dye in a fluorometric plate reader. |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC941259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF594 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC941259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF594 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCA1259-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), APC conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCAP1259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCAP1259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC611259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF660R conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC611259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF660R conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNUM1259-50 |
Biotium |
50uL |
EUR 474 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), 1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCP1259-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), PerCP conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCR1259-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), RPE conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNUB1259-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Concentration: 0.2mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNUB1259-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Concentration: 0.2mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC431259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF543 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC431259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF543 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC051259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405M conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC051259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405M conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC401259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF640R conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC401259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF640R conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC811259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680R conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC811259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680R conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC881259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF488A conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC881259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF488A conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC801259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC801259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF680 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCH1259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCH1259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC041259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405S conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC041259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF405S conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC681259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF568 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC681259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF568 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC701259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF770 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC701259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF770 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC551259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF555 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC551259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF555 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCB1259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Biotin conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNCB1259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), Biotin conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC471259-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF647 conjugate, Concentration: 0.1mg/mL |
Granzyme B (NK/T-Cell Lymphoma Marker) Antibody |
BNC471259-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Granzyme B (NK/T-Cell Lymphoma Marker), CF647 conjugate, Concentration: 0.1mg/mL |
T-cell leukemia/lymphoma 6 (TCL6) polyclonal antibody |
ABP-PAB-02383 |
Allele Biotech |
100 ug |
Ask for price |
|
T-cell lymphoma, 75 cases (1.1mm), set 3 |
LYM1503 |
Pantomics |
1 |
EUR 354 |
Description: Lymphoma tissue array, set 3, T-cell lymphoma, 150 cores from reactive lymphoid tissues (5 cases) and various T-cell lymphoma (68 cases) tissues in duplicates. IHC data include CD3, CD20, CD15, CD20, bcl2 et al. |
Værtsbakterielle interaktioner i Helicobacter pylori-infektion.
Helicobacter pylori er spiralformede gramnegative bakterier med polær flagella, der lever nær overfladen af den humane gastriske slimhinde. De har udviklet komplicerede mekanismer til at undgå bakteriedræbende syre i gastrisk lumen og for at overleve i nærheden, at binde sig til og kommunikere med det humane gastriske epitel og værtsimmunsystem.
Denne interaktion resulterer undertiden i svær gastrisk patologi. H pylori-infektion er den stærkeste kendte risikofaktor for udvikling af gastroduodenalsår, idet infektion er til stede i 60% -80% gastrisk og 95% af duodenalsår. (1) H pylori er også den første bakterie, der klassificeres som en bestemt kræftfremkaldende stof af Verdenssundhedsorganisationens internationale agentur for kræftforskning på grund af dets epidemiologiske forhold til gastrisk adenocarcinom og gastrisk slimhinde-associeret lymfoide vævslymfom.
(2) I de sidste 25 år, siden H pylori først blev beskrevet og dyrket, blev en komplet Der er sket paradigmeskift i vores kliniske tilgang til disse gastriske sygdomme, og mere finish 20.000 videnskabelige publikationer har vist sig om emnet.
Fra det medicinske synspunkt er H pylori et formidabelt patogen, der er ansvarligt for meget sygelighed og dødelighed i hele verden. Imidlertid forekommer H pylori-infektion i cirka halvdelen af verdens befolkning, hvor sygdom er en undtagelse snarere finish reglen. At forstå, hvordan denne organisme interagerer med sin vært, er essentiel for at formulere en clever strategi til håndtering af dens vigtigste kliniske konsekvenser. Denne gennemgang giver et indblik i H pylori-værtsbakterielle interaktioner.
Fremskridt og løfte om FDG-PET-billeddannelse til kræftpasienthåndtering og onkologisk lægemiddeludvikling.
2 – [(18) F] Fluoro-2-deoxyglucose-positronemissionstomografi (FDG-PET) vurderer en grundlæggende egenskab ved neoplasi, Warburg-effekten. Denne molekylære billeddannelsesteknik tilbyder en komplementær tilgang til anatomisk billeddannelse, der er mere følsom og specifik i visse kræftformer.
FDG-PET er blevet anvendt i vid udstrækning inden for onkologi primært som et iscenesættelses- og genoprettelsesværktøj, der kan vejlede patientpleje. Fordi den nøjagtigt detekterer tilbagevendende eller resterende sygdom, har FDG-PET også et betydeligt potentiale til vurdering af terapirespons. I denne forbindelse kan det forbedre patienthåndtering ved at identificere respondenter tidligt, inden tumorstørrelse reduceres; ikke-svar kan ophøre med meningsløs behandling.
- Endvidere korrelerer en reduktion i FDG-PET-signalet inden for dage eller uger efter påbegyndelse af terapi (for eksempel ved lymfom, ikke-lillecellet lunge og spiserørskræft) signifikant sammenhæng med langvarig overlevelse og andre kliniske slutpunkter, der nu anvendes i lægemiddelgodkendelser.
- Disse fund antyder, at FDG-PET kunne lette lægemiddeludvikling som et tidligt surrogat med klinisk fordel. Denne artikel gennemgår det videnskabelige grundlag for FDG-PET og dens udvikling og anvendelse som et værdifuldt værktøj til billedbehandling af onkologi.
- Dets potentiale til at lette lægemiddeludvikling i syv onkologiske omgivelser (lunge, lymfom, bryst, prostata, sarkom, kolorektal og æggestokk) behandles.
- Anbefalinger inkluderer preliminary validering mod godkendte behandlingsformer, retrospektive analyser til at definere størrelsen af ændringer, der indikerer respons, yderligere prospektiv validering som et surrogat med klinisk fordel, og anvendelse som et fase II / III-forsøgsendepunkt for at fremskynde evaluering og godkendelse af nye regimer og behandlingsformer.
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH1 |
7-04520 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH1 |
7-04521 |
CHI Scientific |
1mg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH2 |
7-04522 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH2 |
7-04523 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH2 |
7-04524 |
CHI Scientific |
1mg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH3 |
7-04525 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH3 |
7-04526 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH3 |
7-04527 |
CHI Scientific |
1mg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH4 |
7-04528 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH4 |
7-04529 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -BH4 |
7-04530 |
CHI Scientific |
1mg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -NWGR |
7-04537 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -NWGR |
7-04538 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 -NWGR |
7-04539 |
CHI Scientific |
1mg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 XL |
7-04543 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 XL |
7-04544 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 XL |
7-04545 |
CHI Scientific |
1mg |
Ask for price |
B-Cell Leukemia/Lymphoma 2 |
PR27249 |
Neuromics |
5 ug |
EUR 229.2 |
Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) ELISA Kit |
DLR-Bcl2-b-48T |
DL Develop |
48T |
EUR 591.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids. |
Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) ELISA Kit |
DLR-Bcl2-b-96T |
DL Develop |
96T |
EUR 769.2 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) in samples from serum, plasma, tissue homogenates or other biological fluids. |
Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) ELISA Kit |
RDR-Bcl2-b-48Tests |
Reddot Biotech |
48 Tests |
EUR 619.2 |
Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) ELISA Kit |
RDR-Bcl2-b-96Tests |
Reddot Biotech |
96 Tests |
EUR 859.2 |
Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) ELISA Kit |
RD-Bcl2-b-48Tests |
Reddot Biotech |
48 Tests |
EUR 592.8 |
Bovine B-Cell Leukemia/Lymphoma 2 (Bcl2) ELISA Kit |
RD-Bcl2-b-96Tests |
Reddot Biotech |
96 Tests |
EUR 820.8 |
Recombinant B-Cell Leukemia/Lymphoma 2 (Bcl2) |
4-RPA778Hu01 |
Cloud-Clone |
-
EUR 442.56
-
EUR 242.40
-
EUR 1329.60
-
EUR 523.20
-
EUR 926.40
-
EUR 372.00
-
EUR 3144.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human B-Cell Leukemia/Lymphoma 2 expressed in: E.coli |
Recombinant B-Cell Leukemia/Lymphoma 2 (Bcl2) |
4-RPA778Mu01 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse B-Cell Leukemia/Lymphoma 2 expressed in: E.coli |
Recombinant B-Cell Leukemia/Lymphoma 2 (Bcl2) |
4-RPA778Ra01 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat B-Cell Leukemia/Lymphoma 2 expressed in: E.coli |
Recombinant Human B-Cell Leukemia/Lymphoma 2 His Tag |
7-04549 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 His Tag |
7-04550 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 His Tag |
7-04551 |
CHI Scientific |
1mg |
Ask for price |
BCL2 B-Cell Leukemia/Lymphoma 2 Human Recombinant Protein |
PROTP10415-7 |
BosterBio |
Regular: 20ug |
EUR 380.4 |
Description: Recombinant Human BCL2 produced in E.coli cells is a non-glycosylated, homodimeric protein containing 210 amino acid chain and having a molecular mass of 23.2kDa. The Human BCL2 is purified by proprietary chromatographic techniques. |
anti-Bcl-2(B cell lymphoma 2) |
LF-PA0178 |
Abfrontier |
100 ul |
EUR 400.8 |
Description: Rabbit polyclonal to Bcl-2(B cell lymphoma 2) |
Recombinant human B-cell lymphoma 6 protein |
P1281 |
FN Test |
100ug |
Ask for price |
|
Description: Recombinant protein for human B-cell lymphoma 6 protein |
Bcl-2 B-Cell Leukemia/Lymphoma 2 Human Recombinant Protein (-BH4) |
PROTP10415 |
BosterBio |
Regular: 10ug |
EUR 380.4 |
Description: Bcl-2 Des BH4 domain (10-30 residues) Human Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 197 amino acids 1-9 and 31-218.;The Bcl-2 is expressed as His-Tag fusion protein and purified by proprietary chromatographic techniques. |
Recombinant Human B-Cell Lymphoma Protein 2 Alpha, His Tag |
7-04531 |
CHI Scientific |
5µg |
Ask for price |
Recombinant Human B-Cell Lymphoma Protein 2 Alpha, His Tag |
7-04532 |
CHI Scientific |
20µg |
Ask for price |
Recombinant Human B-Cell Lymphoma Protein 2 Alpha, His Tag |
7-04533 |
CHI Scientific |
1mg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 XL GST Tag |
7-04546 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 XL GST Tag |
7-04547 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human B-Cell Leukemia/Lymphoma 2 XL GST Tag |
7-04548 |
CHI Scientific |
1mg |
Ask for price |
Human B-Cell Leukemia/Lymphoma 2 (Bcl2) Protein |
20-abx065513 |
Abbexa |
-
EUR 627.60
-
EUR 292.80
-
EUR 1796.40
-
EUR 727.20
-
EUR 460.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Recombinant B-Cell CLL/Lymphoma 2 Like Protein 2 (Bcl2L2) |
4-RPL251Ca01 |
Cloud-Clone |
-
EUR 640.39
-
EUR 295.20
-
EUR 2071.49
-
EUR 770.50
-
EUR 1420.99
-
EUR 504.00
-
EUR 4998.72
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Dog B-Cell CLL/Lymphoma 2 Like Protein 2 expressed in: E.coli |
Recombinant B-Cell CLL/Lymphoma 2 Like Protein 2 (Bcl2L2) |
4-RPL251Hu01 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human B-Cell CLL/Lymphoma 2 Like Protein 2 expressed in: E.coli |
Recombinant B-Cell CLL/Lymphoma 2 Like Protein 2 (Bcl2L2) |
4-RPL251Mu01 |
Cloud-Clone |
-
EUR 582.34
-
EUR 279.60
-
EUR 1853.76
-
EUR 697.92
-
EUR 1275.84
-
EUR 465.60
-
EUR 4454.40
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse B-Cell CLL/Lymphoma 2 Like Protein 2 expressed in: E.coli |
Recombinant B-Cell CLL/Lymphoma 2 Like Protein (Bcl2L) |
4-RPE582Hu01 |
Cloud-Clone |
-
EUR 442.56
-
EUR 242.40
-
EUR 1329.60
-
EUR 523.20
-
EUR 926.40
-
EUR 372.00
-
EUR 3144.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human B-Cell CLL/Lymphoma 2 Like Protein expressed in: E.coli |
Recombinant B-Cell CLL/Lymphoma 2 Like Protein (Bcl2L) |
4-RPE582Mu01 |
Cloud-Clone |
-
EUR 421.06
-
EUR 236.40
-
EUR 1248.96
-
EUR 496.32
-
EUR 872.64
-
EUR 357.60
-
EUR 2942.40
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse B-Cell CLL/Lymphoma 2 Like Protein expressed in: E.coli |
Recombinant B-Cell CLL/Lymphoma 2 Like Protein (Bcl2L) |
4-RPE582Ra01 |
Cloud-Clone |
-
EUR 528.58
-
EUR 265.20
-
EUR 1652.16
-
EUR 630.72
-
EUR 1141.44
-
EUR 429.60
-
EUR 3950.40
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat B-Cell CLL/Lymphoma 2 Like Protein expressed in: E.coli |
B-Cell Leukemia/Lymphoma 2 (Bcl-2) Antibody |
abx019019-100ug |
Abbexa |
100 ug |
EUR 410.4 |
|
B-Cell Leukemia/Lymphoma 2 (Bcl-2) Antibody |
abx413147-01mg |
Abbexa |
0.1 mg |
EUR 526.8 |
|
B-Cell Leukemia/Lymphoma 2 (Bcl-2) Antibody |
abx448522-100ug |
Abbexa |
100 ug |
EUR 627.6 |
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx102594 |
Abbexa |
-
EUR 477.60
-
EUR 159.60
-
EUR 1328.40
-
EUR 644.40
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx102595 |
Abbexa |
-
EUR 493.20
-
EUR 159.60
-
EUR 1362.00
-
EUR 661.20
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx109553 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx171393 |
Abbexa |
-
EUR 376.80
-
EUR 944.40
-
EUR 493.20
-
EUR 184.80
-
EUR 309.60
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx171394 |
Abbexa |
|
|
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx171395 |
Abbexa |
|
|
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx175544 |
Abbexa |
|
|
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx175545 |
Abbexa |
-
EUR 510.00
-
EUR 159.60
-
EUR 1412.40
-
EUR 693.60
-
EUR 393.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx175546 |
Abbexa |
|
|
|
B-Cell Leukemia/Lymphoma 2 (Bcl2) Antibody |
20-abx175547 |
Abbexa |
|
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx148562-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx121300 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx121846 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx125557 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx125558 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx133877 |
Abbexa |
-
EUR 427.20
-
EUR 644.40
-
EUR 260.40
|
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx136153 |
Abbexa |
|
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx137363 |
Abbexa |
-
EUR 844.80
-
EUR 393.60
-
EUR 276.00
|
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx139065-01mg |
Abbexa |
0.1 mg |
EUR 460.8 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx111191 |
Abbexa |
|
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx000596 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx016080-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx018050-100ug |
Abbexa |
100 ug |
EUR 460.8 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx019021-100ug |
Abbexa |
100 ug |
EUR 410.4 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx020100-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx012118-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx012120-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
20-abx009552 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx038146-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx027629-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx027629-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx034669-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx034669-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx031085-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx031085-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx031231-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
B-Cell Leukemia/Lymphoma 2 (BCL2) Antibody |
abx031231-80l |
Abbexa |
80 µl |
EUR 343.2 |
|